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Statistical methods for the analysis
of cancer genome sequencing data
Parmigiani G, Lin J, Boca S, Sjo¨blom T, Kinzler KW, Velculescu VE, Vogelstein B
The Ludwig Center and the Howard Hughes Medical Institute, The Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins.
Abstract
The purpose of cancer genome sequencing studies is to determine the nature and types
of alterations present in a typical cancer and to discover genes mutated at high frequen-
cies. In this article we discuss statistical methods for the analysis of data generated
in these studies. We place special emphasis on a two-stage study design introduced
by Sjo¨blom et al.[1]. In this context, we describe statistical methods for constructing
scores that can be used to prioritize candidate genes for further investigation and to
assess the statistical significance of the candidates thus identified.
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1 Introduction
The systematic investigation of the genomes of human cancers has recently become possible with
improvements in sequencing and bioinformatic technologies. Sjo¨blom et al. [1] determined the
sequence of a set of 13,023 genes termed the consensus coding sequences (CCDS) in colorectal and
breast cancers and provided a catalogue of somatic mutations. In this context, a somatic mutation
is a tumor-specific mutation not present in the germline of the patient whose tumor contained
it. More recently, Greenman et al. [2] investigated somatic mutations in the coding exons of 518
protein kinase genes in a large and diverse set of human cancers. Other projects are under way or
planned, including the Cancer Genome Atlas Project (http://cancergenome.nih.gov/), whose
goal is to identify all the genes mutated in at least 5% of human cancers, across cancer types.
Statistical analysis of the data generated in these studies poses new challenges that are worthy
of careful consideration. Greenman et al. have provided an in-depth analysis of data generated
by one-stage studies [3]. In this article, we present analytic approaches applicable to two-stage
designs. To make optimal use of sequencing resources, Sjo¨blom et al. introduced such a two-stage
design, with the stages termed ”Discovery” and ”Validation”. The Discovery Stage consists of a
catalogue of mutations in all genes considered —for example all genes in the CCDS database. This
permitted selection of the subset of genes that harbored at least one somatic mutation, termed
”Discovered”. This subset was further investigated in a Validation Stage which catalogued somatic
mutations in discovered genes in an independent set of tumor samples. Genes that were mutated
in at least one tumor in the Validation set were termed ”Validated”.
The somatic mutations found in cancers are either ”drivers” or ”passengers” [2]. Driver muta-
tions are causally involved in the neoplastic process and are positively selected for during tumorige-
nesis. Passenger mutations provide no positive or negative selective advantage to the tumor but are
retained by chance during repeated rounds of cell division and clonal expansion. The overarching
goal of the statistical analysis is to identify genes that are most likely to contain driver mutations
on the basis of their mutation type and frequency. This is done by quantifying the evidence that
the mutations in a gene reflect underlying mutation rates that are higher than the passenger rates.
From a statistical standpoint, the following three considerations are critical for this analysis:
Two-Stage Design. The first consideration arises from the two-stage approach. Only genes
that harbor at least one mutation in the Discovery Stage and at least one mutation in the Validation
Stage are considered contenders for further analysis. This screening condition needs to be taken
into account when assessing significance using p-values or other methods that rely on the sampling
distribution of the data, as it removes a large number of possible experimental outcomes.
Coverage. The second consideration is that the number of nucleotides successfully sequenced
is generally smaller than the size of the gene times the number of tumors analyzed. For example,
certain exons may be technically challenging to sequence. It is appropriate to apply stringent
quality criteria to sequencing data, which lead to the exclusion of nucleotides whose sequence could
not be identified with certainty. We refer to the portion of a gene that is successfully investigated as
its ”coverage”. Nucleotides excluded, or not covered, are not eligible for false positive mutations and
should therefore not be included in statistical evaluations. Moreover, when applying corrections
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for multiple testing, coverage should be a consideration for all the genes, including those for which
no mutations were found.
Context. The third consideration is that the precise base and neighboring bases of the muta-
tions that were observed, termed the ”mutation context”, are important. The priority given to a
gene in further studies and the statistical significance of a gene should depend on how mutations
are distributed across contexts.
Sjo¨blom et al. addressed these issues by computing a score, called the Cancer Mutation Preva-
lence (CaMP) score, that provides a ranking of the Validated genes for selecting promising candi-
dates. The CaMP score also provides a heuristic approximation of the false discovery rate (FDR)
associated with lists of genes that were both validated and had a CaMP score that exceeded a
given threshold. More recently, Parmigiani et al. [4], further developed this methodology using an
Empirical Bayes approach similar to that originally proposed in Efron et al. [5]. This more fully
addressed the three challenges described above.
In this article we provide a general notation and and foundation for statistical analysis of cancer
genomes, show how the Empirical Bayes method for false discovery rates can be applied to this
context and discuss alternative possibilities for implementation, compare Empirical Bayes estimates
of false discovery rates to frequentist alternatives in simulated experiments and in experimental
data on the CCDS genes, and present additional aspects of the data analysis that are specific to
the RefSeq study [6]. This article serves as a detailed statistical account of the techniques used in
[4] and [6], and implemented, respectively, in versions 1.0 and 2.0 of the CancerMutationAnalysis
R package.
2 Methods
2.1 Sampling distribution of mutations counts.
While cancer genome sequencing projects produce a wealth of information, for the purposes of this
discussion we will focus on the somatic mutation counts, broken down by gene and context, and
considered separately for the Discovery and Validation Stages. Table 1 summarizes the notation
we will be using. Our discussion refers to a single tumor type, say colorectal cancer. When data
on multiple types is collected, this analysis can simply be repeated.
Statistically, an important component of the analysis is the inference on whether each gene
is mutated at a rate that is increased compared to the passenger mutation rate. This can be
formalized by setting the null hypothesis, for gene g, to be that all the context-specific mutation
rates are the same as the corresponding context-specific passenger rates.
The first step is to derive the sampling distribution under the null hypothesis. For a specific
gene and given mutation rates, we can derive the probability of observing mutation count vectors
Xdmg and Xvmg under a product binomial model, based on the assumptions that mutations occur
independently of each other both within and across contexts. This requires that the occurrence of
a mutation does not change the total number of nucleotides available for other mutations, that is,
that the nucleotides’ contexts are mutually exclusive. In practice, in the Sjo¨blom et al. project, one
3
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Nucleotides M number of mutation contexts.
Ngm number of nucleotides of context m in gene g.
Samples Kd number of samples in the Discovery Stage.
Kv number of samples in the Validation Stage.
K total.
Coverage T dgm number of nucleotides available for a mutation of type m
in gene g in the Discovery Stage.
T vgm number of nucleotides available for a mutation of type m
in gene g in the Validation Stage.
Tgm type-specific total T
d
gm + T
v
gm.
Mutation counts Xdgm number of mutations of type m detected in gene g in the
Discovery Stage.
Xvgm number of mutations of type m detected in gene g in the
Validation Stage.
Xgm type-specific total X
d
gm +X
v
gm.
Xg the vector (Xg1, . . . , XgM).
Uppercase X’s represent random variables; lowercase x’s represent experimentally observed results
Mutation rates θdm probability of a passenger mutation in a nucleotide of
context m in the Discovery Stage.
θvm probability of a passenger mutation in a nucleotide of
context m in the Validation Stage.
θm probability of a passenger mutation in a nucleotide of
context m, when common to both Stages.
θdgm probability of a mutation in a nucleotide of context m in
gene g in the Discovery Stage.
θvgm probability of a mutation in a nucleotide of context m in
gene g in the Validation Stage.
θgm probability of a mutation in a nucleotide of context m
gene g in, when common to both Stages.
Table 1: Summary of notation for the data produced by the study for gene g.
of the mutation types is indels (insertion-deletion mutations), which is applicable to all nucleotides,
while others are nonsynonymous point mutations, which are catalogued in six mutually exclusive
contexts. Each nucleotide is therefore susceptible to two types of mutations. However, given
the large number of available nucleotides compared to the mutation rates, the assumption that
the occurrence of a mutation does not change the total number of nucleotides available for other
mutations is likely to have negligible effects. A refinement of this approach could consider a product
of multinomial distributions.
Consider one gene at the time. Because the experiment’s stopping rule is to continue sampling
for gene g only if at least one mutation is found in the discovery phase, the sampling distribution
takes two different forms depending on whether sequencing stops at the discovery or continues to
validation. Define b(x|N, θ) the Binomial density for x successes in N independent trials each with
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success probability θ. If we stop at discovery then maxm(xdg) = 0 and the sampling distribution is
Pr
(
max
m
(Xdg ) = 0|T dg1, . . . , T dgM , θg1, . . . , θgM
)
=
M∏
m=1
b(0|T dgm, θgm) (1)
If we continue to validation then maxm(xdg) > 0 and the sampling distribution is
Pr(Xdg = x
d
g, X
v
g = x
v
g|T dg1, . . . , T dgM , T vg1, . . . , T vgM , θ1, . . . , θM ) =
M∏
m=1
b(xdgm|T dgm, θm)b(xvgm|T vgm, θm) (2)
Under the null hypothesis, mutations in all the genes occur at a common passenger rate θm
for mutation type m. Call G the set of genes that are discovered, that is such that maxm(xdg) > 0.
The overall sampling distribution under the is
Pr(Data|Coverage,Passenger Rates) =∏
g∈GC
M∏
m=1
b(0|T dgm, θm)
∏
g∈G
M∏
m=1
b(xdgm|T dgm, θm)b(xvgm|T vgm, θm) (3)
In some cases it may be important to consider separate mutation rates for the Discovery and
Validation Stages. For example, the Discovery Stage may employ cell lines while the Validation
Stage may employ primary tumor samples. These two types of genomes may harbor different
passenger mutation rates as a result of disparate selection conditions and different numbers of
generations and bottlenecks through which the cells have traversed. When that is the case, using
again the notation of Table 1, the sampling distribution becomes
Pr(Data|Coverage,Passenger Rates) =∏
g∈GC
M∏
m=1
b(0|T dgm, θdm)
∏
g∈G
M∏
m=1
b(xdgm|T dgm, θdm)b(xvgm|T vgm, θvm) (4)
2.2 The CaMP score
In Sjo¨blom et al. we introduced the cancer mutation prevalence (CaMP) score, to provide a ranking
of the Validated genes and select promising candidates. We define it formally here, based on the
following algorithm. First, we compute
pg =
M∏
m=1
b(xgm|Tgm, θm) (5)
if the passenger rates are common to Discovery and Validation, and
pg =
M∏
m=1
b(xdgm|T dgm, θdm)b(xvgm|T vgm, θvm). (6)
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if the passenger rates are allowed to differ in Discovery and Validation. Note that expression (6)
does not collapse to expression (5) when θdm = θvm. More generally, the scale of the two versions of
pg is different and cannot be compared across the two analyses.
We then rank the pg’s and call qg the resulting ranks. The CaMP score is
CaMPg(xdg1, . . . , x
d
gM , x
v
g1, . . . , x
v
gM ) = −∞ if maxm{xdgm} = 0
CaMPg(xdg1, . . . , x
d
gM , x
v
g1, . . . , x
v
gM ) = −∞ if maxm{xvgm} = 0
CaMPg(xdg1, . . . , x
d
gM , x
v
g1, . . . , x
v
gM ) = − log10(Gpg/qg) otherwise
(7)
The top two rows correspond to genes that are eliminated at the Discovery and Validation Stages.
The goal of the CaMP score is to rank genes according to the strength of the evidence that
they may be mutated at rates higher than the passenger rates. When passenger rates are common
to both stages, Sjo¨blom et al.pg can also be used as a heuristic approximation to the p-value
to provide an estimate of the false discovery rate associated with lists of candidate genes drawn
in the basis of CaMP. When this is done, a threshold of 1 on the CaMP score was considered
sufficient by Sjo¨blom et al. to generate a list with estimated FDR of 10%. The pg score is not a
tail probability, as p-values should be. However, for very small rates, the approximation can be
accurate, as discussed in Section 3.2.
2.3 False Discovery Rates
The false discovery rate (FDR) is defined as the estimated proportion of false discoveries among
a set of reported discoveries [7], and has become popular for reporting uncertainty about the
result of screening experiments whose goals are to identify lists of candidates for further biological
evaluation. To address all three of the challenges described in the introduction, we suggest that
the FDR can be optimally evaluated using an Empirical Bayes approach [5]. In such approaches,
one computes a data summary, or score, that captures departure from the null hypothesis, such
as a p-value, a likelihood ratio test (LRT) or other statistics. Examples specific to mutation
analysis are given in Section 2.5. Then, via theoretical arguments or simulation, one determines
the genomic distribution of this score under the assumption that no genes are real discoveries (the
null distribution). For a given threshold, the counts of genes whose score is above a threshold in the
observed and null distributions gives information on the FDR at that threshold. Such approaches
do not necessarily require the calculation of p-values and have a variety of other theoretical and
practical advantages [8, 9].
The notation used here follows that of [9]. Let δg ∈ {0, 1} denote the indicator of whether gene
g is a reported discovery (in the Sjo¨blom study whether gene g is a CAN gene), let D =
∑G
g=1 δg
denote the total number of discoveries, and let rg ∈ {0, 1} denote the unknown truth (in the Sjo¨blom
study an indicator of whether gene g is truly mutated above the passenger rates in cancer). The
false discovery rate is defined as FDR = (
∑
(1− rg)δg)/D, the fraction of false discoveries, relative
to the total number of discoveries. This ratio is unknown and needs to be estimated. Let zg
denote some univariate summary score for the g-th gene, such that larger values of zg are stronger
evidence against the gene’s null hypothesis. Examples are the negative log of a p-value or the log
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of the LRT. Two-sided versions are also available, but are not considered here as the mutation
analysis situation is naturally one-sided. Assume an i.i.d. sampling model for zg, from a mixture
distribution f(·) with terms f0 and f1 that describe the variation of the scores across genes within
the subpopulations of truly mutated genes and not, respectively. Formally this distribution has
the form
zg ∼ pi f0(zg) + (1− pi) f1(zg) ≡ f(zg).
where pi is the proportion of truly null genes. Using the unknown true status variables rg introduced
earlier, the mixture is equivalent to the two-stage model:
p(zg | rg = j) = fj(zg) and Pr(rg = 0) = pi (8)
The distribution f is generally empirically observable, while f0, f1 and pi need to be estimated.
It is common to estimate f0 by permutation of class labels or by direct simulation from the
null, if possible. In our analysis, the null distribution of a score can be obtained by simulating
mutations at the passenger rates in a way that precisely replicates the two-stage experimental plan.
Specifically, for the Discovery Stage, we consider each gene in turn and simulate the number of
mutations of each type from a binomial distribution with success probability equal to the context-
specific passenger rate. The number of available nucleotides in each context is the number of
successfully sequenced nucleotides for that particular context and gene in the samples studied in
the Discovery Stage. For all genes in which at least one mutation is generated in this simulation, the
process is repeated, this time with the number of samples used in the Validation Stage. Potentially,
a different passenger mutation rate may be used in the Validation Stage than was used in the
Discovery Stage of the simulations. We finally apply to the simulated data any filters that were
applied to the experimental data, for example excluding genes whose mutation rates are below a
given threshold.
Estimation of pi is more complex. Assuming pi = 1 provides a practical and conservative
alternative when the proportion of true discoveries is low. However, a better upper bound can be
obtained as follows. We start by constructing histograms of the observed and simulated values of
zg for all genes, using bins of one unit in the log 10 scale. As an example, set zg = − log10 pg,
and consider the bin ranging from 0 to 1, which is composed mostly of genes with no mutations.
Suppose that there are 1000 experimental genes and 1050 simulated genes in that bin. The 1000
genes include both passengers and non-passengers, while the 1050 should contain only passengers.
Thus we can conclude that the number of passengers in the simulated set is too large and that pi is
at most 1000/1050. Because this argument can be applied to all bins, we can estimate pi to be the
reciprocal of the largest ratio between the simulated and observed bin counts. Estimates of pi are
stable over a wide range of bin sizes. This method is an adaptation of the approach proposed in
Efron et al. [5]. In their approach, bin counts are modeled as a function of the scores using Poisson
regression. In our case, a similar smoothing is achieved more simply by binning neighboring score
values.
For given estimates of f0 and pi, the Empirical Bayesian false discovery rate [8] considers genes
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generated by the condition {zg ≥ z} and is
Fdr(z) ≡ piF¯0(z)/F¯ (z)
where z is a threshold, and F¯ (z) = Pr{zg ≥ z}. Even though this is technically not a posterior
probability, it earned a Bayesian name because of the use of Bayes theorem to find the probability of
false discovery given the observation that zg ≥ z, which can be shown to be equivalent to the defined
Fdr statistic [8] above. The probability statement is in the context of the assumed mixture model,
for assumed known f0, f1 and pi. However, the Fdr statistic provides an excellent approximation
for the predictive probability that a hypothetical additional gene randomly drawn from the same
population, and exceeding the threshold, would be a real discovery P (rG+1 = 1 | zG+1 ≥ z, Y ), if
one were to use a full Bayesian model with flexible priors on f1 and f0 [10]. There is also a close
connection between the empirical Bayes procedure proposed in [5] and the frequentist approach
to control FDR using the Benjamini-Hochberg [11] procedure. Specifically, the empirical Bayes
procedure can be shown to provide an upper bound to the frequentist FDR [8].
An additional technical difficulty arises because the Validation Stage was carried out only for a
small and highly nonrandom subset of genes. However, as long as the score zg is defined to take its
minimum value, or −∞, unless the Discovery and Validation Stages are passed, using the observed
proportion of scores exceeding a finite threshold z still provides an unbiased estimate for F (z).
2.4 Passenger Probabilities
While FDRs are statements about lists of genes, gene-specific assessments of uncertainty are also
interesting. From a Bayesian standpoint, one would use the evidence more efficiently by condi-
tioning on zg rather than {zg ≥ z}, as can be proven using decision theoretic arguments [12]. In
the EB approach, one makes gene-specific statements using the so-called local false discovery rate
(fdr) [5], that is
fdr(z) ≡ pif0(z)/f(z).
In terms of the mixture model, and conditioning on f0, f1 and pi, the fdr statistic is the ”passenger
probability” or the probability that a gene with score z is mutated at the passenger rates, fdr(z) =
Pr(rg = 1 | zg = z, Y, f0, f1, pi). As before, one can argue that under a sufficiently flexible prior
probability model on f0, f1, pi, reasonable point estimates can be substituted for the unknown
quantities, allowing us to interpret fdr’s as posterior probabilities, without reference to a specific
prior model [10].
2.5 Scores for Empirical Bayes analysis
Both the FDR and passenger probability analyses rely on the selection of a score for ranking the
genes. Several options are available. An intuitive approach is to choose − log10 pg, as this quantity
captures in a natural way the information about context and coverage. A closely related score
is the LRT [3, 13] for the null hypothesis that all the contexts are mutated at passenger rates,
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analyzed one gene at the time. For a gene such that we perform both discovery and validation, the
LRT is the ratio p∗g/pg, where p∗g is
p∗g =
M∏
m=1
b(xgm|Tgm, θˆgm) (9)
and θˆgm are the experimentally observed rates. Because mutations are rare, variation in the
p∗g terms across genes is small and the LRT is strongly associated with the pg score, with rank
correlations in excess of 99% in relevant experimental situations. The LRT can be generalized
straightforwardly to the case when separate rates are used in Discovery and Validation.
An alternative set of scores can be constructed using frequentist p-values, obtained by evaluating
the gene-specific probability of exceeding the observed value of a score of interest. If zg is the score
for gene g, then, keeping in mind that genes that are not validated are by definition not eligible to
be declared significant, the frequentist p-value for the significance of the gene is
p-valueg = Pr{maxm {X
d
g1, . . . , X
d
gM} > 0 and maxm {X
v
g1, . . . , X
d
gM} > 0 and
Zg(Xdg1, . . . , X
d
gM , X
v
g1, . . . , X
d
gM ) ≥ zg|Tg1, . . . , TgM , θ1, . . . , θm} (10)
where Zg is the random variable defined by mapping the experimental outcome on the scores’
space. To express this as a more conventional tail probability one can equivalently define Zg to
take the value −∞ when maxm{Xdg1, . . . , XdgM} = 0 or maxm{Xvg1, . . . , XdgM} = 0.
This p-value can be used directly in the Benjamini-Hochberg (BH) algorithm [11] or other
procedures for controlling frequentist FDR. The use of frequentist p-values coupled with BH ad-
justment has been suggested as an alternative to the original analysis of Sjo¨blom et al. in three
recent Technical Comments [14, 13, 15] to that paper.
Even when Zg is a function only of the vector xg the expression above differs from a binomial
tail probability in that fewer outcomes are possible. For example, consider the case when there is
only one type and two mutations are found: breaking things down into Discovery and Validation,
a binomial tail probability would add up the probabilities of three cases: (0, 2), (1, 1), (2, 0), while
under the two-stage design with exclusion of the non-validated genes, only the (1, 1) case is relevant
for the p-value calculation.
More generally, consider a gene g for which we performed both stages of the two-stage design and
found mutations in both. The mutation data is then such that maxm(Xdgm) > 0 and maxm(Xvgm) >
0. When passenger rates are constant across stages, the probability of observing x = (x1, ..., xM )
satisfying these constraints, for the p-value calculation, can be expressed as:
Pr(Xg = x|Tg1, . . . , TgM , θ1, . . . , θM ) =
M∏
m=1
b(xm|Tgm, θm)−
M∏
m=1
b(0|T dgm, θm)
M∏
m=1
b(xm|T vgm, θm)−
M∏
m=1
b(xm|T dgm, θm)
M∏
m=1
b(0|T vgm, θm).
9
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bTable 2: Scores used for Empirical Bayes analyses.
Method Score∗ Two Stages Mutation Context Label used in Figure 1
Included Included
S pg Not Appl. Yes Sjo¨blom
F Forrest No No Forrest
GF Getz, Forrest No Yes Getz
R Rubin Yes No Rubin
GB Getz (Appendix B) Yes Yes
∗Forrest and Cavet described two p-values, one used in GF and one used in F; Getz also described
two p-values, one in the main text of their Comment and one in their appendix B. Their conclusions
in the main text were based on the GF p-values and did not incorporate those in Appendix B. Getz
et al. also suggest using the Likelihood Ratio Test (LRT). As noted, the rank correlation of the LRT
with pg is so high that there is no need to consider it separately from pg.
Replacing the expression for the Binomial density in the expression above and rearranging terms
one obtains:
Pr(Xg = x|Tg1, . . . , TgM , θ1, . . . , θM ) =[
M∏
m=1
(
Tgm
xm
)
−
M∏
m=1
(
T vgm
xm
)
−
M∏
m=1
(
T dgm
xm
)] M∏
m=1
θxmm (1− θm)Tgm−xm (11)
When Binomial probabilities are small, Binomial distributions could also be accurately approx-
imated using the Poisson distributions. This approach leads to the following expression
Pr(Xg = x|Tg1, . . . , TgM , θ1, . . . , θM ) ≈[
M∏
m=1
T xmgm
xm!
−
M∏
m=1
(T dgm)
xm
xm!
−
M∏
m=1
(T vgm)
xm
xm!
]
M∏
m=1
θxmm e
−Tgmθm .
Here we considered four types of p-values, representative of the approaches suggested in the
Technical Comments. The four p-value types differed by whether they accounted for the two-stage
design, context, neither or both. The issue of coverage needs to be addressed by EB approaches
in this case, because the p-value is 1 for all genes that are not discovered, irrespective of coverage.
The “context-independent” approach is to set zg to be the total number of mutations found in
gene g irrespective of context, and compute the p-value as the probability of observing a total
that is as large or larger. The “context-specific”, by contrast, is to use the pg as a one-dimensional
summary of the vector of mutation counts and compute the p-value as the probability of a pg as
small or smaller. Approaches accounting for the two stages use expression (10) for determining
the tail probability, while approaches not accounting for the two stages use a product of binomials.
Accounting for the two-stages in the p-value calculations significantly increases the computational
10
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Context Breast Colon
External 2.0 Internal External 2.0 Internal
C or G in CpG 2.990 4.339 6.188 7.730 13.678 14.658
C or G in TpC or GpA 2.480 4.288 6.115 0.960 1.363 1.460
A 0.760 1.200 1.711 0.560 0.768 0.823
C not in CpG or TpC 1.380 1.680 2.397 0.950 1.464 1.569
G not in CpG or GpA 1.070 1.687 2.406 0.850 1.201 1.287
T 0.300 0.489 0.697 0.510 0.860 0.922
ins del 0.097 0.155 0.222 0.079 0.128 0.138
Table 3: Passenger rates scenarios (mutations per Mb)
burden. Abbreviations for these p-values are summarized in Table 2. For clarity, we use the names
of the lead authors of the Technical Comments to identify the corresponding approaches.
3 Results
3.1 Passenger Rates
Determination of passenger rates is complex and controversial. See [4] for a discussion of some
of the challenges. For the analyses presented here, we consider three sets of rates, summarized
in Table 3. The External rates are based on the prior studies described in [4]. The rates for
non-synonymous point mutations are determined so that the overall mutation rate, when applied
to the CCDS genes, is set at 1.2 mutations per Mb. This is the rate used by Sjo¨blom et al. and is
more then twice the experimentally determined passenger rate. The rate for insertions and deletion
is set so that, at a rate of 1.2 mutations per Mb, the passengers’ ratio of non-synonymous point
mutations and indels is the same as that observed in the Discovery Stage. This results in a lower
estimate than used in Sjo¨blom et al., where it was assumed that the indels rates were much higher
than the rates observed in the Discovery Stage. This assumption was unnecessarily conservative,
as the Discovery Stage rate itself provided a theoretical upper bound.
The analysis assumed that the mutation spectrum observed in the study was no different from
that of unselected passenger mutations and that both were a result of the same underlying processes
and exposures to exogenous agents.
The Internal rates were calculated by eliminating all the Validated genes, and assuming that
the remainder were harbor only passenger mutations. These rates constitute an upper bound to the
true passenger rates as long as there are fewer passenger mutations in the validated gene set than
there are non-passenger mutations in the set of genes that were discovered but not validated. This
circumstance is highly plausible, though not estimable from this data without risking circularity.
The rates labeled 2.0 are determined in the same way except that the factor 1.2 is replaced by 2.0,
providing an intermediate scenario. This was the rate used by Rubin and Green.
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F R GF GB S
AUC 0.916 0.916 0.923 0.923 0.921
True Sensitivity: Frequentist 0.697 0.788 0.848 0.922 0.994
True Sensitivity: Empirical Bayes 0.978 0.979 0.980 0.982 0.978
True FDR: Frequentist 0.012 0.027 0.036 0.059 0.112
True FDR: Empirical Bayes 0.105 0.105 0.103 0.103 0.103
Table 4: Performance of alternative methodologies using a genome of 12521 passengers and
500 non-passengers
3.2 Simulation Results
In this section we consider simulation experiments in which a known number of non-passenger
genes is included in the simulated genomes. Specifically, we consider genomes composed of 500
genes mutated at rates above the passenger rates, and 12521 genes mutated at the breast cancer
passenger rates. Such cancer genomes are consistent with the results of Sjo¨blom et al. but have
the advantage that, in the simulated case, we know exactly which genes are passengers and which
are not. We simulated the mutations observed in each non-passenger by assigning it the rate
empirically observed in one of the validated genes in breast cancer, randomly chosen.
For each method, we computed the true proportion of false discoveries in lists formed using
a nominal FDR of 10%. A well calibrated method is one wherein the true proportion of false
discoveries is also 10%. If the true proportion is lower, the method is unnecessarily conservative in
setting the threshold. We perform this calculation with both the Benjamini-Hochberg correction
(labeled Frequentist in the table) and with the EB correction. The EB values are within Monte
Carlo error of the correct value of 10% and show no bias. The Frequentist values are biased towards
lower values, i.e. they are too conservative. For example, the true FDR was actually only 1% in
method F and 4% in method GF, whereas it should be 10% for both. The original Sjo¨blom et al.
method, consisting of applying the Benjamini-Hochberg correction directly to pg is .112, provides
a slightly anticonservative estimate, as expected given the nature of the approximation.
Table 4 also indicates the sensitivity of the various approaches when assessed through simula-
tion. Sensitivity is defined as the proportion of validated non-passengers that are included in the
lists drawn using a nominal 10% FDR. As the task at hand is to identify non-passengers among
validated genes, this is the relevant sensitivity to consider. The results emphasize the high pro-
portion of true discoveries that are missed by the frequentist methods as a result of the lack of
calibration. One of the reasons for the poor performance (technically bias, or lack of calibration)
of the frequentist approaches is that, when no mutations are found in a gene, p-values are equal
to one, irrespective of gene size, context, and coverage. Therefore, any method that estimates the
FDR based only on the mutated genes will end up ignoring critical information about the vast
majority of the analyzed genes.
These conclusions remain true over a broad range of choices for the total number of non-
passengers. The extent of the biases will depend on the specific distribution of rates for non-
12
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F R GF GB S
AUC 0.893 0.893 0.907 0.907 0.900
True Sensitivity: Frequentist 0.520 0.566 0.679 0.749 0.953
True Sensitivity: Empirical Bayes 0.738 0.735 0.779 0.776 0.762
True FDR: Frequentist 0.019 0.031 0.057 0.092 0.283
True FDR: Empirical Bayes 0.109 0.112 0.113 0.111 0.111
Table 5: Performance of alternative methodologies using a genome of 12521 passengers and
500 non-passengers assuming a higher passenger mutation rate
passengers.
The results of simulations including non-passengers and using the Internal or 2.0 rates instead
of the External rates are shown in Table 5. The major conclusions indicated earlier remain true, as
all the methods used to draw the conclusions in the Technical Comments retain a large bias. The
frequentist method that employs two-stages and context specific p-values (method GB) is now less
biased, while the method of Sjo¨blom et al.(method S) is more biased than before. With EB, the
FDR obtained with both the GB and S methods are identical (11.1%), close to the intended FDR
of 10%.
Finally, table S4 shows the discrimination performance of the four sets of p-values for distin-
guishing between drivers and passengers, as measured by the area under the ROC curve (AUC).
The results indicate that the small differences in ranking between CaMP and other methods do
not translate into a loss of discrimination: the CaMP score offers the same discrimination between
passengers and non-passengers as do the most discriminating among the scores proposed in the
Technical Comments. The AUC for scores that account for context is higher than that for methods
that do not, though in the scenario examined here the AUC is high in both cases.
3.3 Experimental Results on CCDS Genes
We now move to a comparison of the analytic approaches presented so far on the data generated
by Sjo¨blom et al. One of the most important aspects of all approaches is the ranking of the
candidate genes that will be used to prioritize them for future studies. The ranking of genes
by cancer mutation prevalence (CaMP) scores is similar to that provided by the other statistical
methods used. The rank correlations between CaMP and all the methods proposed in the Technical
Comments are greater than 0.85.
Next, in Table 6, we consider the results of a simulation that enumerates the genes that are
mutated in the Discovery and Validation Stages when generating data from passenger rates. The
results show that one would expect only about 17 genes to be mutated in both the Discovery and
the Validation Stages for either breast or colorectal cancers, while 137 and 105 genes were actually
found to be mutated in the Validation Stage of the experiment. The remaining genes (120 and 88)
are therefore expected to be mutated at higher than passenger rates.
To compare the effect of the alternative passenger rates on the FDR, we used each in turn in
13
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Table 6: Comparison of experimental results to the simulated results of a genome consisting
entirely of passengers.
Number of genes Number of genes
in Discovery in Validation
Colon Observed 519 105
Simulated 255 16 (s.d. 4)
Breast Observed 673 137
Simulated 264 17 (s.d. 4)
Sjoblom Getz Rubin Forrest
Fig. 1: Proportion of CAN−genes expected to be mutated above background 
 according to various statistical models. See SOM for details.
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our EB analysis, which properly accounts for the three issues outlined in the introduction. The
differences between the analyses are minimal, as shown in Figure 3.3. A reanalysis of the results in
Figure 1 using Internal and 2.0 rates instead of External rates is presented in table 7. While it is
true that increasing the passenger rates will increase the FDR of the CAN-gene list, the lists retain
FDR’s that support the conclusions of the Sjo¨blom et al. study, for the reasons discussed above.
In particular, the conclusion that a large number of genes are mutated at rates greater than the
passenger rate is confirmed: 61 to 95 of the CAN-genes identified in breast cancers and 41 to 49
of the CAN-genes identified in colorectal cancers are predicted to be mutated at frequencies above
these higher passenger mutation rates based on table 7.
4 Additional Methodology used in Wood et al.
Wood et al. introduced several modifications for the analysis of the larger number of genes included
in the RefSeq database. These included 1) a more detailed classification of mutations types; 2)
a more accurate accounting of coverage; 3) different approaches to the estimation of passenger
14
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Method 2.0 Internal
Breast Colon Breast Colon
S 0.235 0.306 0.481 0.359
GF 0.232 0.315 0.474 0.376
F 0.250 0.306 0.506 0.360
R 0.247 0.306 0.506 0.360
GB 0.228 0.337 0.474 0.401
Table 7: Estimated False Discovery Rates for for the top 69 genes in colon and top 123 genes
in breast assuming higher passenger mutation rates
rates; 4) the use of passenger probabilities rather then false discovery rates as the main measure
of statistical uncertainty; 5) an additional phase of validation which required a different analytic
approach.
4.1 Mutation Types, Coverage, and Passenger Rates.
The classification of mutation types in Wood et al. included 24 possible nonsynonymous substi-
tutions, plus indels, giving M = 25. The types are listed in Tables 8 and 9. The calculation
of coverage also differed between Sjo¨blom et al.and Wood et al. , not only because the number
of mutation types was different, but also because of inclusion of a factor that takes into account
gene-specific differences in potential nonsynonymous mutations. When considering base pair sub-
stitution mutations, Wood et al. considered only nucleotides-at-risk, that is those nucleotides that
could result in a non-synonymous mutation when altered. The nucleotides-at-risk were determined
for each gene, in a way broadly similar to that used by Greenman et al. [2]. For example, missense
mutations at the third position of many codons would not result in a nonsynonymous mutation so
were excluded from consideration. In both studies, all the nucleotides successfully sequenced are
considered to be available for indels.
To determine passenger mutation rates, three independent approaches were used, termed ”Ex-
ternal”, ”SNP” and ”NS/S” for nonsynonymous over synonymous. The External rates in colorectal
cancers were determined using experimentally observed rates of mutations in noncoding sequences
in variant detection oligonucleotide microarrays, as described in [6]. This led to an estimate of 0.55
nonsynonymous mutations/Mb, based on
0.55 = 1.2× 0.5× (1− 0.16) + 0.6× 0.5× 0.16
Here 1.2 is the observed rate of mutations per Mb in non-coding diploid DNA, .5 is the fraction of
non-coding diploid DNA, and .16 is the fraction of haploid tumors. The External rate for breast
cancers was assumed to be 0.33 nonsynonymous mutations/Mb.
The SNP-based and NS/S-based approaches both estimate the passenger mutation rates from
the synonymous mutations discovered in the study by first determining the expected nonsynony-
mous to synonymous mutation ratios. These were estimated in two ways. In the SNP-based case
15
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Contexts External SNP: Dis SNP: Val NS/S: Dis NS/S: Val
C to G in CpG 0.196 0.831 0.438 2.149 1.132
C to A in CpG 0.115 0.489 0.258 1.264 0.666
C to T in CpG 0.658 2.785 1.469 7.206 3.794
G to C in CpG 0.219 0.928 0.490 2.402 1.265
G to A in CpG 0.923 3.908 2.062 10.114 5.326
G to T in CpG 0.196 0.831 0.438 2.149 1.132
C to G in TpC 0.595 2.516 1.327 6.512 3.429
C to A in TpC 0.158 0.667 0.352 1.726 0.909
C to T in TpC 0.423 1.789 0.944 4.629 2.437
G to C in GpA 0.648 2.743 1.447 7.098 3.737
G to A in GpA 0.377 1.596 0.842 4.131 2.175
G to T in GpA 0.186 0.787 0.415 2.036 1.072
A to C 0.051 0.215 0.113 0.557 0.293
A to G 0.102 0.430 0.227 1.114 0.586
A to T 0.074 0.314 0.166 0.813 0.428
C to G not in CpG or TpC 0.098 0.415 0.219 1.073 0.565
C to A not in CpG or TpC 0.127 0.538 0.284 1.393 0.733
C to T not in CpG or TpC 0.119 0.503 0.265 1.301 0.685
G to C not in CpG or GpA 0.092 0.391 0.206 1.012 0.533
G to A not in CpG or GpA 0.191 0.810 0.427 2.095 1.103
G to T not in CpG or GpA 0.140 0.591 0.312 1.530 0.806
T to C 0.049 0.208 0.110 0.539 0.284
T to G 0.033 0.139 0.073 0.359 0.189
T to A 0.046 0.194 0.103 0.503 0.265
indels 0.030 0.120 0.060 0.320 0.170
Table 8: Passenger mutation rates used in the Wood et al. study to analyze mutations in
breast tumors.
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Contexts External SNP: Dis SNP: Val NS/S: Dis NS/S: Val
C to G in CpG 0.109 0.198 0.289 0.468 0.680
C to A in CpG 0.196 0.357 0.520 0.843 1.225
C to T in CpG 4.515 8.202 11.954 19.393 28.168
G to C in CpG 0.131 0.238 0.346 0.562 0.816
G to A in CpG 5.212 9.470 13.802 22.391 32.523
G to T in CpG 0.327 0.594 0.866 1.405 2.041
C to G in TpC 0.244 0.443 0.645 1.047 1.520
C to A in TpC 0.149 0.271 0.394 0.640 0.929
C to T in TpC 0.284 0.516 0.753 1.221 1.773
G to C in GpA 0.110 0.201 0.292 0.474 0.689
G to A in GpA 0.401 0.729 1.063 1.725 2.505
G to T in GpA 0.321 0.584 0.850 1.380 2.004
A to C 0.083 0.151 0.220 0.357 0.518
A to G 0.119 0.217 0.316 0.513 0.745
A to T 0.096 0.174 0.254 0.413 0.599
C to G not in CpG or TpC 0.063 0.114 0.167 0.271 0.393
C to A not in CpG or TpC 0.158 0.286 0.417 0.677 0.983
C to T not in CpG or TpC 0.158 0.286 0.417 0.677 0.983
G to C not in CpG or GpA 0.081 0.148 0.215 0.349 0.507
G to A not in CpG or GpA 0.260 0.472 0.688 1.117 1.622
G to T not in CpG or GpA 0.211 0.384 0.559 0.907 1.318
T to C 0.096 0.175 0.254 0.413 0.600
T to G 0.105 0.191 0.279 0.453 0.658
T to A 0.062 0.113 0.164 0.266 0.387
indels 0.040 0.070 0.100 0.150 0.210
Table 9: Passenger mutation rates used in the Wood et al. study to analyze mutations in
colorectal tumors.
17
Hosted by The Berkeley Electronic Press
we calculated this ratio based on coding SNPs identified in previous sequencing studies [16, 3]. The
ratio of nonsynonymous (NS) to synonymous (S) mutations in these studies was 1.02. This ratio
may be an underestimate of the true passenger mutation rate because the selection against NS
mutations may be more stringent in the germline than during tumor development. In the NS/S-
based approaches we therefore determined the NS/S ratio as follows. Context-specific mutation
rates were used to determine the expected frequency of mutations that would create NS vs. S
mutations. Each nucleotide of each codon was mutated in silico to determine whether a particular
change would result in a NS or S change, thereby accounting for all possible changes to all bases of
each codon. The fraction of changes resulting in NS and S alterations were adjusted to account for
the type of base that was mutated, the base change that resulted from the mutation, the immediate
5’ and 3’ neighbors to the mutated base, and codon usage. Through analysis of all RefSeq genes,
we determined that the expected NS/S ratios were 2.41 and 2.65 in colorectal and breast cancers,
respectively. These estimates provide a theoretical upper bound to the true mutation rate because
they do not take into account the fact that nonsynonymous mutations that retard cell growth will
be selected against during tumorigenesis.
The products of these ratios and the observed synonymous mutation rates in each screen yielded
the two different estimates of the passenger mutation rates, termed ”SNP” and ”NS/S” respec-
tively. For example, the rate of synonymous mutations in the colorectal cancer Discovery Screen
was 0.97 mutations/Mb. The SNP-based passenger rate was therefore estimated to be 0.99 NS
mutations/Mb (=0.97 x 1.02) while the NS/S-based passenger rate was 2.35 NS mutations/Mb
(=0.97 x 2.41). These were further broken down by context according to the relative frequency of
observed mutation types. The complete set of rates is given in Tables 8 and 9.
4.2 Analysis of mutation prevalence study.
In addition to the Discovery and Validation stages, Wood et al. experimentally tested 40 CAN-
genes in a separate cohort of 96 cancers. Because the process of selection of these 40 genes for
further study could not be easily represented in terms of mutation counts, it was difficult to generate
reference distributions such as the ones used to compute passenger probabilities for the Discovery
and Validation Screens. We therefore developed an analytic method designed to be insensitive to
the selection process. For this we used the Empirical Bayes approach of Section 2.3 to estimate
of the probability pig of gene g being a passenger, and used this as our prior probability. For each
of the 40 genes in the mutation prevalence study, we then computed a Bayes Factor, based on the
results of the mutation prevalence study alone, for the hypothesis that the gene was mutated at
the passenger mutation rate. Computation of the Bayes Factor requires specification of a prior
distribution of mutation rates that corresponds to the alternative hypothesis. To construct this
distribution, we assumed that, for each of non-passenger gene, each of the non-passenger mutation
rates θ′gm followed Gamma distributions
θ′gm ∼ Ga(α, βm)
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These are assumed to have the same shape parameter α and scale parameters βm set so that the
mean non-passenger rates are equal to the corresponding passenger mutation rates multiplied by
a single scaling factor φ common to all contexts, that is
βm =
α− 1
φθm
.
We next assumed that mutations have a Poisson distribution. This formulation was preferred
to the binomial for computational convenience: using standard conjugate analysis calculations we
can integrate out the θm’s and operate with marginal distributions that depend on α and φ only.
For the null case of passenger mutation rates we set φ = 1 and set the shape parameter to a fixed
value that allows for a very small amount of variation in the rates. In this way both the null and
the alternative model have the same dimensionality.
The shape parameter α and the scaling factor φ were estimated empirically as follows. Drawing
from the prior probabilities we randomly assigned each of the 140 CAN-genes to a true status
of either passenger or non-passenger. We then estimated α and φ by maximizing the marginal
likelihood. For each draw, we evaluated the Bayes’ factor at the estimated α and φ and used Bayes’
rule to combine the prior and Bayes Factor into the posterior probabilities. We then averaged the
posterior probabilities over draws to determine the final estimate. Posterior estimates varied only
slightly across draws. This method controlled for multiple testing via the prior distribution, which
is the local false discovery rate from the Empirical Bayes analysis.
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